Halozyme Therapeutics | HALO - Market Capitalization


Halozyme Therapeutics reported $9.09B in Market Capitalization this June of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.8B 724M Mar/2026
Agios Pharmaceuticals USD 2.01B 423M Mar/2026
Alnylam Pharmaceuticals USD 44.15B 8.39B Mar/2026
Amarin USD 290M 51M Dec/2025
Amgen USD 189.89B 13.64B Mar/2026
Baxter International USD 8.67B 1.15B Mar/2026
Cara Therapeutics USD 366M 338M Sep/2025
Cytokinetics USD 8.19B 420M Mar/2026
DBV Technologies USD 274M 17M Sep/2025
Eli Lilly USD 869.02B 146.97B Mar/2026
Esperion Therapeutics USD 885M 351M Dec/2025
Halozyme Therapeutics USD 7.66B 257M Mar/2026
Ionis Pharmaceuticals USD 12.46B 356M Mar/2026
MannKind USD 757M 984M Mar/2026
Nektar Therapeutics USD 11.91B 11.05B Jun/2026
Pfizer USD 153.81B 12.24B Mar/2026
United Therapeutics USD 25.19B 4.21B Mar/2026
Vanda Pharmaceuticals USD 279M 6M Dec/2024